News
6hon MSN
Gilead Sciences, Inc. (NASDAQ: GILD) is one of the. The company announced that the US FDA approved Yeztugo ® (lenacapavir), ...
2d
allAfrica.com on MSNUganda: HIV Prevention - Daily Oral Versus Long-Acting InjectablesWinning Founding Managing Editor and Executive Director of Cns (Citizen News Service) and Is a Feminist, Health and Development Justice Advocate.
“This is a historic day in the decades-long fight against HIV,” Gilead CEO Daniel O’Day said in the company’s announcement.
The US Food and Drug Administration has approved Yeztugo (lenacapavir), an injectable HIV-1 capsid inhibitor, as preexposure prophylaxis (PrEP) to reduce the risk for sexually acquired HIV.
Right now, more than 400,000 people in the United States use pills to prevent HIV, The Wall Street Journal pre-exposure prophylaxis. Gilead expects the number of users to top 1 million by the next ...
Gilead Sciences Inc. (GILD) announced that the U.S. Food and Drug Administration has approved Yeztugo (lenacapavir)-the company's injectable HIV-1 capsid inhibitor-as pre-exposure ...
Right now, more than 400,000 people in the United States use pills to prevent HIV, The Wall Street Journal added. These medications are referred to as PrEP, short for pre-exposure prophylaxis.
A drug called lenacapavir, administered in two injections a year, offers protection from HIV comparable to daily pills. One ...
The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...
Gilead Sciences received approval from the Food and Drug Administration for its injectible pre-exposure prophylaxis (PrEP) designed to reduce the risk of sexually transmitted HIV. The drug, known ...
Trisha Goddard rose to fame as a TV journalist. She was the first black TV presenter in Australia and is best known in the UK for her eponymous TV show which aired on ITV and Channel 5 in the late 90s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results